Skip to main content

Muscular Dystrophy Association (MDA), 2026

Filter
Close
Content type:
Efficacy and safety of rozanolixizumab treatment cycles in patients with generalized myasthenia gravis: Final pooled analysis of Phase 3 studies
Ali A. Habib, Carlo Antozzi, Artur Drużdż, et al.
Poster
Improvement of ocular subdomain scores with zilucoplan in patients with generalized myasthenia gravis in RAISE and RAISE-XT studies
M. Isabel Leite, Saskia Bresch, Miriam Freimer, et al.
Poster
Sustained minimal symptom expression in generalized myasthenia gravis: A 120-week post hoc analysis of RAISE-XT
Channa Hewamadduma, Saskia Bresch, Miriam Freimer, et al.
Poster
Switching to rozanolixizumab from efgartigimod: Real-world outcomes in patients with generalized myasthenia gravis in the United States
Alexandria Harrold, Thaïs Tarancón, Kristina Bardenheuer, et al.
Poster
Quality of life in patients with generalized myasthenia gravis receiving rozanolixizumab: Post hoc analysis of MycarinG
Sabrina Sacconi, Carlo Antozzi, Elena Cortés-Vicente, et al.
Poster
Disease course and healthcare burden of thymidine kinase 2 deficiency (TK2d) in Rady Children’s Hospital patients
Sarah Chang, Edwin F Juárez, Yuanjun Ma, et al.
Poster
Genetic Prevalence of Thymidine Kinase 2-Related Mitochondrial Disease: A Combined Approach Using Clinical Literature and Large-Scale Genomic Databases
Austin Larson, Amina Kozaric, Kaja Zarakowska, et al.
Poster